Caitlin Maureen Mcmaster, MS, OTR/L | |
906 Cr 6, Alma, CO 80420 | |
(970) 412-3369 | |
Not Available |
Full Name | Caitlin Maureen Mcmaster |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 906 Cr 6, Alma, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306624937 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | OT.0006768 (Colorado) | Primary |
Mailing Address | Practice Location Address |
---|---|
Caitlin Maureen Mcmaster, MS, OTR/L Po Box 2062, Breckenridge, CO 80424-2031 Ph: (970) 412-3369 | Caitlin Maureen Mcmaster, MS, OTR/L 906 Cr 6, Alma, CO 80420 Ph: (970) 412-3369 |
News Archive
Today at the 93rd General Session and Exhibition of the International Association for Dental Research, researcher Aderonke A. Akinkugbe, University of North Carolina at Chapel Hill, USA, will present a study titled "Environmental Tobacco Smoke is Associated With Periodontitis in U.S. Non-smokers."
Cannabis use is much more common among pregnant women with depression and pregnant women with depression are more than 3 times more likely to use cannabis than those without depression, according to a new study at Columbia University Mailman School of Public Health.
Data from two standard diagnostic tests commonly obtained in children evaluated for abdominal pain-when combined-can improve the ability of emergency department physicians and pediatric surgeons to identify those patients who should be sent to the operating room for prompt removal of an inflamed appendix; those who may be admitted for observation; and those who may safely be discharged home, according to a new study published online as an "article in press" in the Journal of the American College of Surgeons.
Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010.
› Verified 4 days ago